Neurotrophic factors decrease the release of creatine kinase and prostaglandin E2 from metabolically stressed muscle

Neuromuscular Disorders

Volumn 8, Issue 1, 1998, Pages 7-13

  Lian, Ji Dong ^a   Al Jumah, Mohammed ^a   Cwik, Valerie ^a   Brooke, Michael H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Creatine kinase; Metabolic stress; Neurotrophic factors; Prostaglandin E2

Indexed keywords

2,4 DINITROPHENOL; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CREATINE KINASE; NEUROTROPHIC FACTOR; PROSTAGLANDIN E2; SOMATOMEDIN C;

ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ENZYME RELEASE; MALE; MUSCLE INJURY; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CREATINE KINASE; DINITROPHENOLS; DINOPROSTONE; HYPOXANTHINE; INSULIN-LIKE GROWTH FACTOR I; MALE; MUSCLE, SKELETAL; MUSCULAR DISEASES; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; XANTHINE OXIDASE;

EID: 0032007386     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(97)00122-3     Document Type: Article

References (36)

1. 2 in calcium ionophore-stimulated rat muscle. Prostaglandins Leukotrienes Essent Fatty Acids 1995;53:117-122.
2. [2] Majumdar R, Cwik VA, Brooke MH. Evidence of two mechanisms of prostaglandin release in an in vitro model of muscle damage. Possible therapeutic implications. Neuromuscul Disord 1994;4:483-488.
3. 2 from metabolically stressed muscle. Biochem Pharmacol 1994;48:371-374.
4. 2 release from metabolically stressed skeletal muscle. Can J Neurol Sci 1994;21:120-124.
5. [5] Brooke MH, Choksi R, Kaiser KK. Inosine monophosphate production is proportional to muscle force in vitro. Neurology 1986;36:288-291.
6. [6] Rosalki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 1967;69:696-700.
7. [7] Duncan CJ, Jackson MJ. Different mechanisms mediate structural changes and intracellular enzyme efflux following damage to skeletal muscle. J Cell Sci 1987;87(Pt 1):183-188.
8. [8] Helliwell TR, Jackson MJ, Phoenix J, MacLennan P, West-Jordan J, Edwards RH. Immunohistochemical and biochemical indicators of muscle damage in vitro: the stability of control muscle and the effects of dinitrophenol and calcium ionophore. Int J Exp Pathol 1994;75(5):329-343.
9. [9] Kawahara H, Houdou S, Inoue T. Scanning electron microscopic observations on muscle cells of experimental mitochondrial myopathy produced by 2,4-dinitrophenol. J Submicrosc Cytol Pathol 1991;23:397-403.
10. [10] Majumdar R, Cwik VA, Solonynko G, Brooke MH. Relationship of oxypurine release to contractile failure in dinitrophenol treated rat muscle. Acta Physiol Scand 1993;149:249-255.
11. [11] Heller SL, Brooke MH, Choksi R, Kaiser KK. 2-4,-Dinitrophenol, muscle biopsy and McArdle disease. Neurology 1988;38:15-19.
12. [12] Heller SL, Choksi R, Brooke MH. IMP response: an indicator of metabolic stress in working muscle. Muscle Nerve 1986;9:515-518.
13. 2 release from isolated Duchenne muscle. Neurology 1991;41:101-104.
14. [14] Lindsay RM. Neurotrophic growth factors and neurodegenerative diseases: Therapeutic potential of the neurotrophins and ciliary neurotrophic factor. Neurobiol Aging 1994;15:249-251.
15. [15] The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. Clin Neuropharmacol 1995;18:515-532.
16. [16] Dore S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997;20:326-331.
17. [17] Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, Schmalbruch H, Kahn A. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 1997;3:429-436.
18. [18] Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science 1994;265:1107-1110.
19. [19] Ikeda K, Klinkosz B, Greene T. et al. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol 1995;37:505-511.
20. [20] Al-Jumah M, Lian J-D, Cwik VE, Brooke MH. The demonstration of TrKB tyrosine protein kinase B receptors in skeletal muscle. Neurology 1997;48:A268.
21. [21] Fennyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Altered neurotrophin mRNA levels in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 1995;64:1231-1237.
22. [22] Ip NY, McClain J, Barrezueta NX, Aldrich TH, Pan L, Li Y, Wiegand SJ, Friedman B, Davis S, Yancopoulos GD. The a-chain of the CNTF receptor is required for signalling and defines potential CNTF targets in the adult and during development. Neuron 1993;10:89-102.
23. [23] Ip NY, Yancopoulos GD. Receptors and signalling pathways of ciliary neurotrophic factor and the neurotrophins. Sem Neurosci 1993;5:249-257.
24. [24] Adler R, Landa K, Manthorpe M, Varon S. Cholinergic neuronotrophic factors: intraocular distribution of soluble trophic activity for ciliary neurons. Science 1979;204:1434-1436.
25. [25] Eide FF, Lowenstein DH, Reichardt LF. Neurotrophins and their receptors - current concepts and implications for neurologic disease. Exp Neurol 1993;121:200-214.
26. [26] Helgren ME, Squinto SP, Davis HL, Parry DJ, Boulton TG. et al. Trophic effects of ciliary neurotrophic factor on denervated skeletal muscle. Cell 1994;76:1-20.
27. [27] Cheng B, Mattson MP. NGF and bNGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron 1991;7:1031-1041.
28. [28] Mattson MP, Cheng B. Growth factors protect neurons against excitotoxic/ischemic damage by stabilizing calcium homeostasis. Stroke 1993;24(Suppl 12):I136-140.
29. [29] Lewis ME, Neff NT, Contreras PC. et al. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993;124:73-88.
30. [30] Mattson MP, Zhang Y, Bose S. Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp Neurol 1993;121:1-13.
31. [31] Sendtner M, Dittrich F, Hughes RA, Thoenen H. Actions of CNTF and neurotrophins on degenerating motoneurons: preclinical studies and clinical implications. J Neurol Sci 1994;124(Suppl):77-83.
32. [32] Zhang Y, Tatsuno T, Carney JM, Mattson MP. Basic, FGF, NGF, and IGFs protect hippocampal and cortical neurons against iron-induced degeneration. J Cerebral Blood Flow Metab 1993;13:378-388.
33. [33] Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 1992;59:99-106.
34. [34] Jackson GR, Apffel K, Werrbach-Perez K, Perez-Polo JR. Role of nerve growth factor in oxidant-antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance. J Neurosci Res 1990;25:360-368.
35. [35] Pan Z, Perez-Polo R. Role of nerve growth factor in oxidant homeostasis: glutathione metabolism. J Neurochem 1993;6:1713-1722.
36. [36] Sampath D, Jackson GR, Werrbach-Perez K, Perez-Polo JR. Effects of nerve growth factor on glutathione peroxidase and catalase in PC12 cells. J Neurochem 1994;62:2476-2479.